Hoffmann-La Roche AG's PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered "Cured"
Published: May 22, 2007
WASHINGTON--(BUSINESS WIRE)--Results from a new study, presented at the 38th annual Digestive Disease Week (DDW) conference, showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS® (peginterferon alfa-2a) had no detectable virus up to seven years later – validating the use of the word “cured” to describe these patients, according to study authors. Currently, the best indicator of treatment success is a sustained viral response (SVR), defined as undetectable hepatitis C virus in the blood six months after the end of treatment. The results announced today are from a long-term follow-up study to determine whether the virus re-emerges in patients who achieve an SVR. (Studies show that, overall, about half of patients with hepatitis C monoinfection can achieve an SVR with PEGASYS and ribavirin treatment, the current standard of care.)